课题基金 / 基金详情

Safety and Tolerability of Deferoxamine in Acute Cerebral Hemorrhage

Safety and Tolerability of Deferoxamine in Acute Cerebral Hemorrhage
去铁胺治疗急性脑出血的安全性和耐受性
批准号:
7755382
负责人:
Magdy H Selim
金额:
$18.42万
依托单位国家:
美国
项目类别:
财政年份:
2008
资助国家:
美国
项目状态:
已结题
起止时间:
2008-01-15 至 2011-12-31

项目摘要

项目成果

Magdy H Selim的其他基金

相似基金

相关文献

中文摘要
翻译
描述(申请人提供):几项动物研究表明,血红蛋白分解和随后在脑内积聚的铁在脑出血(ICH)后的继发性神经元损伤和脑水肿中发挥作用;铁螯合剂治疗,如去铁胺(DFO),可提供神经保护。去铁胺广泛应用于临床已有30多年的历史。它耐受性好,价格低廉,因此,可能是治疗脑出血患者的一种潜在的新疗法。到目前为止,还没有临床研究来检验DFO对脑出血患者的影响。我们建议进行一项前瞻性、开放标签、非随机、多层次、剂量发现、多中心、初步临床研究,以评估DFO治疗脑出血患者的安全性和耐受性。我们将测试递增剂量方案,从7毫克/公斤开始,最高剂量为125毫克/公斤。将采用剂量毒性的连续再评估方法来确定递增剂量水平,剂量级之间的最大增量不超过25 mg/kg。该药物将在中风症状出现后12小时内每天静脉滴注,连续3天。受试者将接受长达90天的重复临床评估,并在服药前和服药后进行CT成像。我们的主要目标是:1)通过确定与治疗相关的不良事件,评估不同剂量DFO在脑出血患者中的安全性和耐受性;2)确定在随后的II/III期研究中采用的最大耐受剂量,以确定最佳治疗时间窗口和持续时间,并测试DFO在改善脑出血后预后方面的有效性。我们假设DFO耐受性良好,对脑出血患者的严重不良反应最小。这项研究将提供将临床前有效策略应用于脑出血治疗的机会,并将使我们能够制定药物管理的后勤工作,并实施指导未来II/III期试验规划所需的标准化程序。这一结果可能会考虑到改善脑出血患者预后的新方法。ICH是致残和死亡的常见原因。一项成功的研究证明了铁修饰疗法的有效性,这将对公共卫生具有相当大的意义。
英文摘要
DESCRIPTION (provided by applicant): Several animal studies show that hemoglobin breakdown and subsequent iron accumulation in the brain play a role in mediating secondary neuronal injury and brain edema after intracerebral hemorrhage (ICH); and that treatment with iron chelators, such as deferoxamine (DFO), provides neuroprotection. Deferoxamine has been extensively used in clinical practice for more than 30 years. It is well-tolerated, inexpensive, and therefore, may be a potential novel therapy to treat patients with ICH. To date, there have been no clinical studies to examine the effects of DFO in patients with ICH. We propose to conduct a prospective, open-label, non-randomized, multiple-tier, dose-finding, multi-center, preliminary, clinical study to evaluate the safety and tolerability of treatment with DFO in patients with ICH. We will test escalating dose-regimens, starting at a dose of 7 mg/kg up to a maximum dose of 125 mg/kg. A Continuous Reassessment Method of dose toxicity will be used to determine escalating dose levels, and the maximal increment increase between dose-tiers will not exceed 25 mg/kg. The drug will be administered as IV infusion daily for 3 consecutive days, starting within 12 hours of stroke symptom onset. Subjects will undergo repeated clinical assessments up to 90 days, and CT imaging pre- and post-drug administration. Our main objectives are: 1) to evaluate the safety and tolerability of varying doses of DFO, by determining the treatment related adverse events, in patients with ICH; and 2) to determine the maximal tolerated dose to be adopted in subsequent phase II/III studies to determine the optimal treatment time window, and duration, and to test the efficacy of DFO in improving outcome after ICH. We hypothesize that DFO is well-tolerated and has minimal serious adverse effects in patients with ICH. This study will afford the opportunity to apply preclinical efficacious strategy to the treatment of ICH, and will allow us to work out the logistics of drug administration, and implementation of standardized procedures needed to guide the planning of future phase II/III trials. The results can potentially bring into account new means to improve the outcome of patients with ICH. ICH is a frequent cause of disability and death. A successful study demonstrating the efficacy of iron-modifying therapy would be of considerable public health significance.
期刊论文(4)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1161/strokeaha.111.000031
发表时间: 2013-06
期刊: Stroke
影响因子: 8.3
作者: [Yeatts SD]
通讯作者: Yeatts SD
DOI: 10.1161/strokeaha.117.019541
发表时间: 2018-05
期刊: Stroke
影响因子: 8.3
作者: [Hemorrhagic Stroke Academia Industry (HEADS) Roundtable Participants]
通讯作者: Hemorrhagic Stroke Academia Industry (HEADS) Roundtable Participants
StAtins Use in intRacereberal hemorrhage patieNts MRI (SATURN MRI) Ancillary Study
StATins Use in intRacerebral hemorrhage patieNts (SATURN)
StATins Use in intRacerebral hemorrhage patieNts (SATURN)
Futility Study of Deferoxamine Mesylate in Intracerebral Hemorrhage (i-DEF)
海外基金